Jump to content

Jeffrey Hubbell

Add links
From Wikipedia, the free encyclopedia
Jeffrey Hubbell
Born
North Kansas City, Missouri, US
Academic background
Education
ThesisVisualization and Analysis of Mural Thrombogenesis (Platelet Adhesion, Collagen, Polyurethane, Digital Image Processing) (1986)
Academic work
Institutions

Jeffrey Alan Hubbell is an American bioengineering working immunoengineering. His research has focused on topics from physical biology, biomaterials, regenerative medicine, and translational immunology.

Early life and education

[edit]

He received his bachelor's degree from Kansas State University and his PhD from Rice University, both in chemical engineering.[1] His doctoral mentor was Larry V. McIntire, in a project addressing the biophysics of thrombosis.[2]

Career

[edit]

Upon completing his PhD, Hubbell joined the Chemical Engineering Department at the University of Texas. In 1995, he moved to the Division of Chemistry and Chemical Engineering at Caltech, and then in 1997 to the Institute of Biomedical Engineering at ETH Zurich and the University of Zurich.

In 2003 Hubbell joined the faculty at Switzerland's École Polytechnique Fédérale de Lausanne (EPFL) where he served as the founding director of the Institute of Bioengineering.[3] Hubbell remained in Switzerland until 2014 when he accepted a position at the University of Chicago faculty of the Pritzker School of Molecular Engineering as their Barry L. MacLean Professor for Molecular Engineering Innovation and Enterprise.[3] By 2017, Hubbell was the recipient of the Society for Biomaterials’ Founders Award for his "long-term, landmark contributions to the discipline of biomaterials." He was specifically recognized for designing materials to assemble and function so they could stimulate the immune system to fight infection or malignancy and coining the term "immuno-modulatory materials."[4] In the same year, Hubbell was awarded the Acta Biomaterialia Gold Medal[5] and appointed the inaugural Bell Professor in Tissue Engineering at the University of Chicago.[6]

In 1995, Hubbell was elected a fellow of the American Institute for Medical and Biological Engineering for his "fundamental and clinically-applied contributions to biomaterials."[7] In 2010, he was elected to the National Academy of Engineering “for contributions to the science, engineering, and technology of bioactive materials for the benefit of patients.”[8] Upon joining the University of Chicago, Hubbell collaborated with Cathryn Nagler to establish the ClostraBio, a company to develop drugs.[9] In 2018, Hubbell was also elected a Member of the National Academy of Medicine for his work "pioneering the development of cell responsive (bioactive) materials and inventing biomaterials that are now widely utilized in regenerative medicine."[10] Following this, he helped develop a vaccine platform for infectious disease.[11] In 2021, Hubbell was one of eight University of Chicago faculty members elected to the American Academy of Arts and Sciences.[12] In 2023, he as elected to the third national academy, the National Academy of Sciences.[13][14] He was also elected a fellow of the National Academy of Inventors.[15]

As to recent research, in 2019[16] and 2023,[17] Hubbell and colleagues, including D. Scott Wilson,[18] published an approach to inverse vaccination, with implications for treatment of autoimmunity. In April 2020, Hubbell, Melody Swartz, and Jun Ishihara[19] co-published their research on an immunotherapy delivery system that finds tumors by seeking out and binding to the tumors’ collagen.[20] Following this development, he helped design a new therapy to eventually assist those with autoimmune diseases by fusing a tolerogenic cytokine to a blood protein that accumulates in the lymph nodes.[21]

References

[edit]
  1. ^ "Jeffrey Hubbell". University of Chicago. Retrieved June 11, 2021.
  2. ^ Hubbell, J. A.; McIntire, L. V. (November 1986). "Platelet active concentration profiles near growing thrombi. A mathematical consideration". Biophysical Journal. 50 (5): 937–945. doi:10.1016/S0006-3495(86)83535-4. ISSN 0006-3495. PMC 1329819. PMID 3790695.
  3. ^ a b "UChicago faculty members receive named, distinguished service professorships". University of Chicago. November 11, 2014. Retrieved June 14, 2021.
  4. ^ Borzo, Greg (May 9, 2017). "Jeffrey Hubbell honored for landmark biomaterials research". University of Chicago. Retrieved June 14, 2021.
  5. ^ "Jeffrey Hubbell, recipient of the 2018 Acta Biomaterialia Gold Medal". Materials Today. November 3, 2017. Retrieved June 14, 2021.
  6. ^ "Jeffrey Hubbell named inaugural Bell Professor in Tissue Engineering". University of Chicago. June 15, 2017. Retrieved June 14, 2021.
  7. ^ "JEFFREY HUBBELL, PH.D." American Institute for Medical and Biological Engineering. Retrieved June 14, 2021.
  8. ^ "Professor Jeffrey Alan Hubbell". NAE Website. Retrieved 2024-10-19.
  9. ^ Reiter, Carla (October 27, 2016). "Scientist builds drug development company out of research lab". University of Chicago. Retrieved June 14, 2021.
  10. ^ "Jeffrey Hubbell named to National Academy of Medicine". University of Chicago. October 19, 2018. Retrieved June 14, 2021.
  11. ^ Ayshford, Emily (February 1, 2019). "New vaccine for malaria developed at IME could be more effective". University of Chicago. Retrieved June 14, 2021.
  12. ^ "Eight UChicago faculty elected to American Academy of Arts and Sciences". University of Chicago. April 23, 2021. Retrieved June 14, 2021.
  13. ^ "National Academy of Sciences Elects Members and International Members - NAS". www.nasonline.org/. Retrieved 2024-10-19.
  14. ^ "Jeffrey Alan Hubbell – NAS". www.nasonline.org/. Retrieved 2024-10-19.
  15. ^ "National Academy of Inventors announces 2014 NAI Fellows". National Academy of Inventors. Retrieved June 14, 2021.
  16. ^ Wilson, D. Scott; Damo, Martina; Hirosue, Sachiko; Raczy, Michal M.; Brünggel, Kym; Diaceri, Giacomo; Quaglia-Thermes, Xavier; Hubbell, Jeffrey A. "Synthetically glycosylated antigens induce antigen-specific tolerance and prevent the onset of diabetes". Nature Biomedical Engineering. 3 (10): 817–829. doi:10.1038/s41551-019-0424-1. ISSN 2157-846X. PMID 31358881.
  17. ^ Tremain, Andrew C.; Wallace, Rachel P.; Lorentz, Kristen M.; Thornley, Thomas B.; Antane, Jennifer T.; Raczy, Michal R.; Reda, Joseph W.; Alpar, Aaron T.; Slezak, Anna J.; Watkins, Elyse A.; Maulloo, Chitavi D.; Budina, Erica; Solanki, Ani; Nguyen, Mindy; Bischoff, David J. "Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses". Nature Biomedical Engineering. 7 (9): 1142–1155. doi:10.1038/s41551-023-01086-2. ISSN 2157-846X. PMID 37679570.
  18. ^ "Scott Wilson". Johns Hopkins Biomedical Engineering. Retrieved 2024-10-20.
  19. ^ "Jun Ishihara". Ishihara laboratory - Imperial College London. Retrieved 2024-10-20.
  20. ^ Ayshford, Emily (April 30, 2020). "Breakthrough helps fight 'cold' tumors that don't respond to immunotherapy". University of Chicago. Retrieved June 14, 2021.
  21. ^ Ayshford, Emily (October 12, 2020). "UChicago researchers find way to improve multiple sclerosis treatment". University of Chicago. Retrieved June 14, 2021.
[edit]

Jeffrey Hubbell publications indexed by Google Scholar

Retrieved from "https://wiki.riteme.site/w/index.php?title=Jeffrey_Hubbell&oldid=1253840321"